Dr. Shirish Gadgeel discusses recent EVOKE-2 trial results showing promising response rates with sacituzumab govitecan combined with pembrolizumab for metastatic non-small cell lung cancer.
When Lung Cancer Took One Lung and COVID Took the Other, a Chicago Police Captain Was Left With Only One Option for Survival
Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection
Applying the Heterogeneous Approach From NSCLC to SCLC
Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers
Repotrectinib Receives NMPA Approval in China for ROS1+ NSCLC
Nivolumab/Chemoradiotherapy Regimen Misses PFS End Point in Unresectable, Locally Advanced NSCLC
Vepdegestrant Plus Palbociclib Sustains Efficacy in Advanced ER+ Breast Cancer
Atezolizumab Plus Chemo Misses Mark in Early-Relapsing Unresectable TNBC
Olaparib/Durvalumab/Fulvestrant Combo Meets PFS End Point in HRR-Altered or MSI ER+/HER2– Breast Cancer
Frontline Atezolizumab Plus Sacituzumab Govitecan Elicits Responses in PD-L1+ Advanced TNBC